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Abstract
The high prevalence of bladder cancer and its recurrence make it an important target for chemoprevention. About
half of invasive urothelial tumors have mutations in p53. We determined the chemopreventive efficacy of a p53-
stabilizing agent, CP-31398, in a transgenic UPII-SV40T mouse model of bladder transitional cell carcinoma (TCC)
that strongly resembles human TCC. After genotyping, six-week-old UPII-SV40T mice (n = 30/group) were fed
control (AIN-76A) or experimental diets containing 150 or 300 ppm of CP-31398 for 34 weeks. Progression of
bladder cancer growth was monitored by magnetic resonance imaging. At 40 weeks of age, all mice were killed;
urinary bladders were collected to determine weights, tumor incidence, and histopathology. There was a signif-
icant increase in bladder weights of transgenic versus wild-type mice (male: 140.2 mg vs 27.3 mg, P < .0001;
female: 34.2 mg vs 14.8 mg, P < .0001). A significant decrease in the bladder tumor weights (by 68.6–80.2%,
P < .0001 in males and by 36.9–55.3%, P < .0001 in females) was observed in CP-31398–treated mice. Invasive
papillary TCC incidence was 100% in transgenic mice fed control diet. Both male and female mice exposed to CP-
31398 showed inhibition of invasive TCC. CP-31398 (300 ppm) completely blocked invasion in female mice. Molecular
analysis of the bladder tumors showed an increase in apoptosis markers (p53, p21, Bax, and Annexin V) with a de-
crease in vascular endothelial growth factor in transgenic mice fed CP-31398. These results suggest that p53-mod-
ulating agents can serve as potential chemopreventive agents for bladder TCC.
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Introduction
Urinary bladder cancer is one of the common cancers worldwide, with
the highest incidence rates in industrialized countries. In 2013, about
72,570 new cases of bladder cancer are expected to be diagnosed
(about 54,610 in men and 17,960 in women), of which approxi-
mately 15,210 will die because of this cancer [1]. Smoking tobacco
and exposure to arsenic are known risk factors for development of
urothelial neoplasms. Urothelial cancers of the bladder generally are
classified into noninvasive and invasive types, which are thought to
originate independently [2,3]. A majority of the urothelial tumors are
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noninvasive, low-grade, papillary transitional cell carcinoma (TCC),
but up to 30% of all diagnosed tumors are classified as invasive TCC
that pose a very high risk for distant metastases. In addition, 10% to
15% of the noninvasive TCC progress to the invasive form with re-
currence after surgery, having acquired additional genetic mutations.
Noninvasive forms of TCC have better treatment options and 5-year
survival (88–98%). However, the management of invasive urothelial
cancers is a major challenge, with a very low 5-year survival rate of only
6% in distantly metastasized cases [1]. Molecular analysis of these two
types of tumors clearly indicates that more than half of the invasive
tumors have mutations in the tumor suppressor genes p53 and pRB
[4–6]. The high prevalence, progression to invasive carcinoma, and fre-
quent tumor recurrence make bladder cancer an important neoplastic
disease for exploration of prevention strategies.
In normal cells, the p53 tumor suppressor gene plays a critical role
in induction of programmed cell death during cellular stress and
DNA damage. In many cancers, p53 is mutated, leading to under-
expression or loss of function; hence, p53 has emerged as an important
target for chemoprevention and therapy. CP-31398, a synthetic styryl-
quinazoline, (N ′-[2-[(E)-2-(4-methoxyphenyl)ethenyl]-quinazolin-
4-yl]-N ,N -dimethylpropane-1,3-diamine hydrochloride)], was
found to restore the DNA-binding activity of mutant p53 protein by
stabilizing the conformation of the DNA-binding domain [7–9]. The
chemopreventive potential of this agent has been demonstrated success-
fully in various in vitro and in vivo tumor efficacy studies [10–12].
Among the preclinical models for urothelial cancer, UPII-SV40T
transgenic mice develop invasive urothelial tumors, similar to those
observed in humans, owing to the expression of Simian virus large
T antigen driven by the urothelium-specific uroplakin II promoter
[13]. Simian virus large T antigen inactivates p53/pRB pathways
[14] and its expression in urothelium was found to drive develop-
ment of bladder tumors in these mice that replicate the invasive uro-
thelial tumors of humans, both genetically and histopathologically [13].
Hence, in the present study, we determined the chemopreventive
efficacy of the p53-stabilizing agent CP-31398 using the UPII-SV40T
transgenic mouse model for invasive urothelial TCC.
Materials and Methods
Animals, Diet, and Care
All animal experiments were done in accordance with the guide-
lines of the Institutional Animal Care and Use Committee. UPII-
SV40T transgenic mice were obtained from Xue-Re Wu at the NYU
Medical Center (New York, NY). The required number of UPII-
SV40T transgenic mice was generated by breeding as described below.
Animals were housed in ventilated cages under standardized conditions
(21°C, 60% humidity, 12-hour light/12-hour dark cycle, 20 air
changes per hour) in the University of Oklahoma Health Sciences
Center Rodent Barrier Facility. Semipurified modified AIN-76A
diet ingredients were purchased from Bioserv, Inc (Frenchtown, NJ).
CP-31398 (Figure 1A) was procured from theNational Cancer Institute
chemoprevention drug repository. CP-31398 (150 and 300 ppm) was
premixed with small quantities of casein and then blended into the diet
using a Hobart mixer. Both control and experimental diets were pre-
pared weekly and stored in a cold room. Agent content in the experi-
mental diets was determined periodically in multiple samples taken
from the top, middle, and bottom portions of individual diet prep-
arations to verify uniform distribution. Mice were allowed ad libitum
access to the respective diets and to automated tap water purified by
reverse osmosis.
Breeding and Genotyping
Heterozygous UPII-SV40T and wild-type mice were maintained
in an FVB genetic background. Male UPII-SV40T mice were
crossed to wild-type females and offspring were generated at required
Figure 1. (A) Structure of p53-stabilizing agent, CP-31398. (B) Experimental design for chemopreventive efficacy evaluation of CP-31398
in UPII-SV40T transgenicmice. At 6 weeks of age, groups (30 per group UPII-SV40T or 12 per groupwild type) ofmice were fed experimental
diets containing 0, 150, or 300 ppm of CP-31398 continuously for 34 weeks and bladders from each mouse were evaluated histopathol-
ogically and also for expression of various markers as described in the text.
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quantities. Transgenic pups were confirmed by tail DNA extraction
and polymerase chain reaction (PCR). Briefly, genomic DNA was
extracted from snap-frozen tail tissue samples using the mini-prep kit
(Invitrogen, Carlsbad, CA). PCR for the SV40T gene was done using
oligonucleotide primer sequences 5′-CTTTGGAGGCTTCTGG-
GATGCAACT-3′ (sense) and 5′-GCATGACTCAAAAAACTTAG-
CAATT-CTG-3′ (antisense) and amplifying under the following PCR
conditions: denaturation at 95°C for 5 minutes, followed by 35 cycles
at 95°C for 1 minute, 58°C for 45 seconds, and 72°C for 45 seconds.
The PCR products, when separated on a 2% agarose gel, showed a
550-bp band.
Bioassay
Genotyped UPII-SV40T transgenic mice were used in the efficacy
study. The experimental protocol is summarized in Figure 1B. Five-
week-old mice were selected and randomized so that the average body
weights in each group were equal (n = 30 UPII-SV40T mice per group
and n = 12 wild-type mice per group) and were fed AIN-76A diet for
1 week. At 6 weeks of age, mice were fed control or experimental diets
containing 0, 150, or 300 ppm of CP-31398 until termination of the
study. Mice were checked routinely for signs of weight loss, toxicity, or
any abnormalities. The food intake and body weight of each animal
were measured once weekly for the first 6 weeks and then once a month
until termination. After 34 weeks on experimental diets, all mice were
killed (at 40 weeks of age) by CO2 asphyxiation and necropsied; urinary
bladders were collected and weighed. To determine the tumor weight,
the average of wild-type (tumor-free) bladder was subtracted from the
weight of tumor-bearing transgenic mouse bladders. A portion of the
urinary bladder was fixed in 10% neutral buffered formalin for histo-
pathologic evaluation and the rest was snap frozen in liquid nitrogen for
further analysis.
Magnetic Resonance Imaging of Urothelial Tumors
Magnetic resonance imaging (MRI) was performed using a 30-cm,
horizontal bore, 7-T magnet (Bruker BioSpin MRI GmbH, Ettlingen,
Germany) at 40 weeks of age on mice fed the control and experimental
diets. For imaging, the mice were anesthetized with 2% isoflurane and
restrained in a cradle for MRI scans. During MRI scans, the animals’
respiratory rate was monitored (SA Instruments, Stony Brook, NY),
and body temperature was maintained at 37°C with a water heating
system (Gaymar T/Pump). Morphologic and contrast-enhanced imag-
ing with gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA;
0.5 mmol/kg body weight, 50-μl volume in sterile saline) were per-
formed on these mice. Gd-DTPA was administered through an i.v.
tail vein catheter.
Tissue Processing and Histologic Analysis
Formalin-fixed, paraffin-embedded tissues were sectioned (4 μm)
and stained with hematoxylin and eosin. Sections of each urothelial
tumor were evaluated histologically by a pathologist blinded to the
experimental groups. Carcinomas were classified into noninvasive car-
cinoma in situ (CIS) and invasive carcinomas (lamina propria–invasive
and muscularis propria–invasive types; Figure 2, E–H ) according to
histopathologic criteria.
Real-time PCR
Total RNA from urothelial tissue and tumor samples of male
mice was extracted using the Totally RNA Kit (Ambion: Life Tech-
nologies, Grand Island, NY) as per the manufacturer’s instructions.
Equal quantities of DNA-free RNA were used in reverse transcription
reactions for making cDNA using SuperScript reverse transcriptase
(Invitrogen). Real-time PCRs were done for p53, Bax, and vascular
endothelial growth factor (VEGF) using SYBRGreen and the following
primers: for p53, 5′-TGAAACGCCGACCTATCCTTA-3′ (sense)
and 5′-GGCACAAACACGAACCTCAAA-3′ (antisense), Tm 60;
for Bax, 5′-CAGGATGCGTCCACCAAGAA-3′ (sense) and 5′-GCAA-
AGTAGAAGAGGGCAACCA-3′ (antisense), Tm 60; for VEGF,
5′-GGAGATCCTTCGAGGAGCACTT-3′ (sense) and 5′-GGCGAT-
TTAGCAGCAGATATAAGAA-3′ (antisense), Tm 60; for
glyceraldehyde phosphate dehydrogenase, 5′-CCTC-GTCCCGTAGA-
CAAAATG-3′ (sense) and 5′-TGAAGGGGTCGTTGATGGC-3′
(antisense), Tm 55. Relative gene expression was calculated using
the 2−ΔΔCT formula [15]. All experiments were performed in at
least triplicates.
Immunohistochemistry
The effects of CP-31398 on the expression of p21 and Annexin V
were evaluated by immunohistochemistry. Briefly, sections of paraffin-
embedded tissues were deparaffinized in xylene, rehydrated through
graded ethanol solutions, and washed in phosphate-buffered saline
(PBS). Antigen retrieval was carried out by heating the sections in
0.01 M citrate buffer (pH 6.0) for 30 minutes in a boiling water bath.
Endogenous peroxidase activity was quenched by incubation in 3%
H2O2 in PBS for 5 minutes. Nonspecific binding sites were blocked
using Protein Block for 20 minutes. Then, sections were incubated
overnight at 4°C with 1:300 dilutions of monoclonal antibodies
against p21 and Annexin V (Santa Cruz Biotechnology, Santa Cruz,
CA). After several washes with PBS, they were incubated with appro-
priate secondary antibody for 2 hours, then exposed to avidin-biotin
complex reagent (Invitrogen). After rinsing with PBS, the slides were
incubated with the chromogen 3,3′-diaminobenzidine for 3 minutes,
then counterstained with hematoxylin. Nonimmune rabbit Igs were
substituted for primary antibodies as negative controls. Specimens
were observed using an Olympus microscope IX71, and digital com-
puter images were recorded with an Olympus DP70 camera. Scoring
was done according to the intensity of the nucleic or cytoplasmic stain-
ing (no staining = 0, weak staining = 1, moderate staining = 2, strong
staining = 3) and prevalence of stained cells (1–10% = 1, 11–20% = 2,
21–50% = 3, and >50% = 4). The final immunoreactive score was
determined by multiplying the intensity scores by the prevalence of
positivity scores of stained cells, yielding a minimum score of 0 and a
maximum score of 12.
Statistical Analysis
The data are presented as means ± standard errors. Differences in
body weights were analyzed by analysis of variance. Statistical differ-
ences between bladder and tumor weights of the control and treated
groups were evaluated using unpaired t test with Welch correction.
Tumor incidences (percentage of mice with urothelial tumors) were
analyzed by Fisher exact test. Differences between control and treat-
ment groups were considered significant at P < .05. All statistical
analyses were performed using Graphpad Prism 5.0 Software.
Results
Weight, Necropsy, and Histopathology
All of the transgenic andwild-typemice of both control and experimen-
tal groups were weighed weekly and monitored throughout the study.
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There was no significant difference in the body weights of the control
and experimental groups (Figure 2B). Gross necropsy observations also
revealed that organs such as stomach, liver, spleen, pancreas, small
intestine, colon, and testes were normal in all animals, while the urinary
bladders (Figure 2A) and kidneys were visibly abnormal and because of
tumor formation. Urinary bladders from all of the transgenic mice
weighed significantly more [∼5.4-fold more for males (147.2 mg vs
27.3 mg, P < .0001; Figure 2C ) and ∼2.4-fold more for females
(34.1 g vs 14.8 g, P < .0001; Figure 2D)] than did those from wild-type
mice. Histopathologic evaluation of these bladders identified that all
the tumors were high-grade papillary invasive type TCC (Table W1).
Magnetic Resonance Imaging
At the end of the study, MRI was performed on experimental mice
fed control or CP-31398 diets. Images fromwild-typemice showed nor-
mal urinary bladder, whereas those from transgenic mice fed control diet
clearly show large, dense tumor formation inside the urinary bladders. In
transgenic mice fed the experimental diet, the bladders showed sig-
nificantly reduced tumor formation (Figure 3A). We observed a good
correlation between the bladder weights and the MRI of the bladders.
Inhibition of Tumor Growth by CP-31398
Urinary bladders of the transgenic and wild-type mice fed control
and experimental diets were weighed at the end of the study. Wild-
type mice fed control and CP-31398 diets showed no significant dif-
ference in bladder weights (27.25 mg vs 25.34 mg, P > .05 for males
and 14.8 mg vs 16.9 mg, P > .05 for females). However, a compari-
son of the bladder weights from the transgenic mice revealed that
CP-31398 treatment lead to marked inhibition (P < .0001) of the
tumor growth. The average tumor mass in the male transgenic mice
was 119.9 mg (control) vs 22.41 mg (150 ppm of CP-31398) vs
40.25 mg (300 ppm of CP-31398; Figure 3B). Similarly, the average
tumor mass in the female transgenic mice was 19.3 mg (control),
12.4 mg (150 ppm of CP-31398), and 8.7 mg (300 ppm of CP-
31398; Figure 3C ). Therefore, treatment of mice with the p53-
stabilizing agent CP-31398 led to 68.5% to 80.2% inhibition of
tumor mass in males with the lower dose showing better effects than
the higher dose but no statistical significance (P > .05) between the
groups. In female mice, there was a dose-dependent 36.9% to 55.3%
inhibition of bladder tumor weights (P < .05).
Inhibition of Tumor Invasion by CP-31398
There was a significant inhibition of urothelial tumor invasion
into the lamina propria and muscularis in CP-31398–treated mice
as determined by histopathology. High-grade TCC with invasion
into lamina propria or muscularis was observed in 100% of the
urinary bladders from mice fed control diet (Table W1). The low
dose of CP-31398 had no effect on the invasion in male mice, but
Figure 2. Upper panels: (A) Urinary bladders of the UPII-SV40T mice increase in both size and weight compared with the wild-type mice.
(B) Terminal body weights of the transgenic mice fed control or experimental diets. (C) Male and (D) female bladder weights (means ±
standard error) at the termination of the experiment. The differences between the wild-type and UPII-SV40T animals fed control diet
were analyzed by unpaired t test with Welch correction. Lower panels: Typical histologic characterization of urothelium showing (E) normal
wild-type or (F) low-grade noninvasive, (G) high-grade noninvasive, and (H) high-grade invasive TCC in UPII-SV40T mice upon feeding with
control AIN-76A diet. No evidence of TCC was seen in the bladders of wild-type mice.
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the high-dose treatment showed 18% inhibition of tumor invasion
(Figure 3D; P > .05). The effect was more profound in the female
mice where only 36% (Figure 3E ; P < .0001) of the mice fed low
dose and none of mice fed the high dose showed tumor invasion
(Figure 3E ; P < .0001). In all of the mice in which invasion was in-
hibited, the urothelium showed noninvasive CIS. Thus, treatment of
mice with CP-31398 at the higher dose suppressed tumor invasion
and limited lesions to CIS.
Modulation of p53, p21, Bax, Annexin V, and VEGF
Expression by CP-31398
Molecular analysis of the urothelium from control and experimental
mice was done using quantitative real-time PCR and immunohisto-
chemistry. Compared with normal urothelium, urinary bladder tumors
exhibited a significant inhibition of proapoptotic proteins p21 (Fig-
ure 5A) and Bax (Figure 4C), whereas VEGF was elevated (Figure 4E).
Treatment of mice with CP-31398 led to an increase in the p53 and
Bax by about three-fold (P < .0001; Figure 4B) and two-fold (P <
.0001; Figure 4D), respectively, with clear accumulation of nuclear
p21 protein (Figure 5, B–D). There was also an increase in Annexin V
expression, suggesting an increase in apoptotic cells upon CP31398
treatment (Figure 5, E–H ). CP-31398 treatment also caused a sig-
nificant inhibition of expression of the angiogenic factor VEGF
(P < .0001; Figure 4F ). These observations suggest that CP-31398
could successfully induce p53, leading to apoptosis and inhibition of
tumor growth.
Discussion
TCC of the urothelium, which constitutes 95% of all urinary bladder
cancers, causes significant morbidity and mortality all over the world.
Cessation of tobacco smoking by active smokers may decrease the risk
for bladder cancer; however, the risk in former smokers does not fall
to the level of those who never smoked [16,17]. Reported data sug-
gest that almost 70% of the bladder cancer cases are still at a non-
invasive stage at the time of diagnosis; however, if the noninvasive
CIS is left untreated, it will progress to high-risk, invasive TCC, and
even if treated, invasive TCC may recur [18].
Various transgenic mouse models with invasive bladder tumors
have been developed [13,19,20] and used to understand tumor
Figure 3. (A) MRI images of the urinary bladders from wild-type and UPII-SV40T transgenic mice. Transgenic mice were given either
control diet or diet containing CP-31398 for 36 weeks. Morphologic and contrast-enhanced imaging (Gd-DTPA administered through
an i.v. tail vein catheter) MRI was performed on these mice at 40 weeks of age. Wild-type urinary bladders do not show any tumors.
Untreated UPII-SV40T mice have large, dense tumor inside the bladder, while the treated transgenic mice have significantly reduced
and barely visible tumor. (B and C) Effect of CP-31398 on bladder tumor weights in male (B) and female (C) mice, respectively, at the
termination of the experiment. CP-31398 treatment led to a significant reduction of tumor weight in both groups. (D and E) CP-31398
treatment had an inhibitory effect on the incidence of invasive TCC in male (D) and female (E) mice, respectively.
970 Chemoprevention of Invasive Urothelial Cancer Madka et al. Neoplasia Vol. 15, No. 8, 2013
Figure 4. Effect of CP-31398 on expression of p53, Bax, and VEGF markers. Quantitative real-time PCR analysis was done on bladder
tumors of male mice as described in Materials and Methods section. (A, C, E) Relative expression of p53, Bax, and VEGF mRNA,
respectively, in UPII-SV40T urothelium compared with wild type. (B, D, F) CP-31398 treatment led to an increase in p53 and Bax, while
VEGF mRNA levels were inhibited.
Figure 5. Effect of CP-31398 on p21 (A–D) and Annexin V (E–H) expression in bladder tumors. Immunohistochemical analysis was
performed with paraffin-embedded and microsectioned bladder tissues from male mice as described in Materials and Methods section.
A significantly increased expression of p21 (A–D) and Annexin V (E–H) was seen in the treatment groups.
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initiation and progression. In addition, bladder cancer induced by the
carcinogenN -butyl-N -(4-hydroxybutyl)-nitrosamine (OH-BBN) [21]
has been used extensively to test drug efficacy [22–27]. Genetically
engineered mice with tissue-specific expression of SV40 T antigen have
been instrumental in elucidating the biology of many cancers. These
mice develop invasive carcinomas in the tissue of expression, e.g., breast
[28], prostate [29], liver [30], pancreas [31], and bladder [13,19], and
have been valuable models for drug development [32,33]. In a recent
study, Liu et al. [34] showed the usefulness of UPII-SV40 T transgenic
mice for urothelial cancer chemoprevention studies using Flavokawain
A as a test agent. Here, we have tested the p53-modulating agent CP-
31398 for chemoprevention of invasive urothelial cancer in UPII-
SV40T transgenic mice.
Chronic administration of 150 and 300 ppm of CP-31398 in both
male and female transgenic mice and wild-type mice did not elicit any
overt toxicities or body weight loss. Dietary CP-31398 administration
significantly suppressed growth of urothelial tumors as evident by
decreased bladder weights in both sexes. That the percent reduction
in tumor weights from male mice was greater than that in female
mice can be explained by the difference in tumor growth rate between
two sexes. In male mice, tumor growth progression seems to be very
aggressive, leading to at least a five-fold increase in bladder weights as
compared with bladder weights from female mice. It is important to
note that CP-31398 showed dose-dependent suppression of invasive
TCC inhibition in female mice, with the higher dose showing
100% inhibition of invasive TCC (Table W1). The mechanisms for
the difference in SV40 T antigen–induced tumor progression in male
versus female mice are not clear, but they may be due, in part, to the
influence of sex hormones on tumor growth [35,36]. Epidemiological
data indicate that men also have a three to four times higher chance
of developing bladder cancer compared with women; however, dif-
ferences between men and women in the rate of tumor progression
have not been studied extensively.
Unlike the dose-dependent effects of CP-31398 in female mice, the
inhibition of bladder tumor weight in male mice did not show dose
dependence. However, CP-31398 administration appears to be effec-
tive in preventing tumor invasion in both male and female mice in
a dose-response manner. Antitumor effects of CP-31398 have been
demonstrated in various in vitro studies using cancer cells with a mu-
tated p53 gene [37–42]. Chemopreventive efficacy of CP-31398 was
also shown in several preclinical models [10–12]. Earlier studies have
demonstrated that CP-31398 blocked UVB-induced skin carcino-
genesis and was associated with increases in p53 [10]. Our laboratory
has shown that dietary administration of CP-31398 significantly in-
hibited intestinal tumor formation in a dose-dependent manner in
APCmin/+ mice [11]. In a rat model of colon cancer, CP-31398 was
found to inhibit 63% of multicrypt aberrant crypt foci and up to
65% of adenocarcinoma multiplicity induced by a chemical carcinogen
[12]. Inhibition of colon adenocarcinoma incidence and multiplicity
was also observed when CP-31398 was combined with the low-dose
cyclooxygenase inhibitor celecoxib in rats [12]. The present study
results further support previous in vivo observations of the chemo-
preventive effects of CP-31398 [10–12]. The difference in efficacy of
CP-31398 between male and female mice was not noted in previous
studies because CP-31398 had not been tested in both male and female
mice simultaneously.
Mutations in p53 protein lead to down-regulation of p21 protein ex-
pression and other downstream molecules involved in p53-dependent
cell proliferation and apoptosis pathways. In the mice fed control diet,
we have seen loss of Bax and p21 expression in urothelial tumors, which
indicates loss of p53 function in these tumors. It is well established that
nuclear localization of p53 activates p21, which blocks cell cycle pro-
gression, both by acting as an inhibitor of cyclin-dependent kinase/
cyclin complexes and by inhibiting DNA replication by binding to
proliferating cell nuclear antigen [43]. We observed a significant
increase in p53, p21, and Bax expression in the tumors from CP-
31398–treated mice, with significant nuclear localization of p53 and
increase in apoptosis. Loss of p21 expression was observed in human
bladder tumors and that loss was identified as a predictor of cancer
progression [43], while induction of p21 was shown to increase apop-
tosis and antitumor effects in bladder cancer in vitro and in vivo [44].
Consistent with these observations, we have observed a loss of p21 ex-
pression in the bladder tumors of mice fed control diet and an in-
duction of this protein and apoptosis in tumors from animals treated
with CP-31398.
Urothelial tumors also overexpress the angiogenesis stimulator
VEGF, which is important for tumor growth and metastasis [45]. Evi-
dence from both patient tumors and preclinical models supports the
role of VEGF as a key mediator of angiogenesis in bladder cancer
[46,47]. Disruption of VEGF signaling was found to impair tumor
growth and vascularity, as well to prevent metastatic spread and to
prolong survival [48]. In the present study, we found approximately
six-fold overexpression of VEGF in tumors, with significant inhibition
in urothelial tumors from the CP-31398–treated mice, suggesting anti-
angiogenic effects of CP-31398. It is not clearly understood how p53
mutations or loss of functional activity lead to increased VEGF and/
or proangiogenic effects in urothelial tumors. It is possible that tumors
with inactivated p53 would have much greater angiogenic potential
because of both increased production of proangiogenic factors such as
VEGF and decreased synthesis of antiangiogenic factors. In support of
this possibility, studies by Zhang et al. [49] showed that introduction
of wild-type p53 into sarcoma cells containing mutant p53 significantly
reduced the expression of VEGF by transcriptional repression. In ad-
dition, loss of p53 in tumor cells enhances hypoxia-inducible factor
(HIF-1α) levels and augments HIF-1–dependent transcriptional ac-
tivation of the VEGF gene in response to hypoxia, suggesting that
hypoxia-induced apoptosis and activation of VEGF are partially de-
pendent on p53 functional activity. Thus, the p53-stabilizing agent
CP-31398 may induce tumor cell inhibition in part by inducing p53/
p21 and inhibiting VEGF expression.
Conclusion
Invasive carcinomas can be prevented if intervention occurs early
enough to block progression by targeting appropriate molecules that
play key roles in this process. Our results suggest that p53-modulating
agents can serve as potential chemopreventive agents for invasive
urothelial cancers. CP-31398 emerged as a promising chemopreventive
agent for various cancers with frequent p53 mutations. Several other
molecules and pathways are also deregulated in bladder cancer. A
combination of CP-31398 and other selective inhibitors such as anti-
VEGF and HIF-1α inhibitors may result in better efficacy and better
management of the disease.
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